Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene- valproic acid

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 2, 1997, Pages 698-703

  Sadeque, Abu J M ^a   Fisher, Michael B ^a   Korzekwa, Kenneth R ^b,c   Gonzalez, Frank J ^b   Rettie, Allan E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 PROPYL 4 PENTENOIC ACID; COUMARIN; CYTOCHROME P450; DIETHYLDITHIOCARBAMIC ACID; MICROSOME ENZYME; SULFAPHENAZOLE; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME POLYMORPHISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; LIVER TOXICITY; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; VALPROIC ACID;

EID: 0030831766     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. ANDERSON, T., MINERS, J. O., VERONESE, M. E., TASSANEEYAKUL, W., MEYER, U. A. AND BIRKETT, D. J.: Identification of human liver cytochrome P-450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 36: 521-530, 1993.
2. AOYAMA, T., GONZALEZ, F. J. AND GELBOIN, H. V.: Human cDNA-expressed cytochrome P450 1A2: Mutagen activation and substrate specificity. Mol. Carcinog. 2: 192-198, 1989.
3. BAILLIE, T.: Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chem. Res. Toxicol. 1: 195-199, 1988.
4. BAILLIE, T.: Metabolism of valproate to hepatotoxic intermediates. Pharm. Weekbl. Sci. 14: 122-125, 1992.
5. BRYANT, A. E., III AND DREIFUSS, F. E.: Valproic acid hepatic fatalities. III. U. S. experience since 1986. Neurology 46: 465-469, 1996.
6. BULLOCK, P., PEARCE, R., DRAPER, A., PODVAL, J., BRACKEN, W., VELTMAN, J., THOMAS, P. AND PARKINSON, A: Induction of liver microsomal cytochrome P450 in cynomologus monkeys. Drug Metab. Dispos. 23: 736-748, 1995.
7. BUSH, E. D., Low, L. K. AND TRAGER, W. F.: A sensitive and specific stable isotope assay for warfarin and its metabolites. Biomed Mass Spectrom. 10: 395-398, 1983.
8. CHANG, T. K., GONZALEZ, F. J. AND WAXMAN, D. J.: Evaluation of triacetylolean-domycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochrome P-450. Arch. Biochem. Biophys. 311: 437-442, 1994.
9. CREAVEN, P. J., PARKE, D. V. AND WILLIAMS, R. T.: A spectrofluorimetric study of the 7-hydroxylation of coumarin by liver microsomes. Biochem. J. 96: 390-398, 1965.
10. CRESPI, C. L., STEIMEL, D. T., AOYAMA, T., GELBOIN, H. V. AND GONZALEZ, F. J.: Stable expression of human cytochrome P4501A2 cDNA in a human lymphoblastoid cell line: role of the enzyme in the metabolic activation of aflatoxin B1. Mol. Carcinog. 3: 5-8, 1990.
11. DREIFUSS, F. E., SANTILLI, N., LANGER, D. H., SWEENEY, K. P., MOLINE, K. A. AND MENANDER, K. B.: Valproic acid hepatic fatalities: a retrospective review. Neurology 37: 379-385, 1987.
12. ESTABROOK, R. W., PETERSON, J., BARON, J. AND HILDEBRANDT, A.: The spectroscopic measurement of cytochromes associated with drug metabolism. Methods Pharmacol. 2: 303-350, 1972.
13. GERBER, N., DICKINSON, R. G., HARLAND, R. C., LYNN, R. K., HOUGHTON, D., ANTONIAS, J. I. AND SCHIMSCHOCK, J. C.: Reye-like syndrome associated with valproic acid. J. Pediatr. 95: 142-144, 1979.
14. HALL, S. D., HAMMAN, M. A., RETTIE A. E., WIENKERS, L. C., TRAGER W. F., VANDENBRANDEN, M. AND WRIGHTON, S. A.: Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab. Dispos. 22: 975-978, 1994.
15. JONES, J. P., HE, M., TRAGER, W. F. AND RETTIE, A. E.: Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab. Dispos. 24: 1-6, 1996.
16. JURIMAROMET, M., ABBOTT, F. S., TANG, W., HUANG, H. S. AND WHITEHOUSE, L. W.: Cytotoxicity of unsaturated metabolites of valproic acid and protection by vitamins C and E in glutathione-depleted rat hepatocytes. Toxicology 112: 69-85, 1996.
17. KASSAHUN, K., Hu, P., GRILLO, M. P., DAVIS, M. R., JIN, L. AND BAILLIE, T. A.: Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. Chem. Biol. Interact. 90: 253-275, 1994.
18. KÖNIG, ST. A., SIEMES, H., BLÄKER, F., BOENIGK, E., GROB-Selbeck, G., Hanefeld, F., Haas, N., Köhler, B., Koelfen, W., Korinthenberg, R., Kurek, E., Lenard, H.-G., Penin, H., Penzien, J. M., Schünke, W., Schultze, C., Stephani, U., Stute, M., Traus, M., Weinmann, H.-M. and Scheffner, D.: Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 35: 1005-1015, 1994.
19. LAWRENCE, F. R., RETTIE, A. E., EDDY, A. C. AND TRAGER, W. F.: Chemical synthesis, absolute configuration, and stereochemistry of formation of 10-hydroxywarfarin: a major oxidative metabolite of (+)-R-warfarin from hepatic microsomal preparations. Chirality 2: 96-105, 1990.
20. LEVY, R. H., RETTENMEIER, A. W., ANDERSON, G. A., WILENSKY, A. J., FRIEL, P. N., BAILLIE, T. A., ACHEAMPONG, A., TOR, J., GUYOT, M. AND LOISEAU, P.: Effects of polytherapy with phenytoin carbamazepine and stiripentol on formation of 4 ene-valproate, a hepatotoxic metabolite of valproic acid. Clin. Pharmacol. Ther. 48: 225-235, 1990.
21. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. AND RANDALL, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-272, 1951.
22. MANCY, A., BROTO, P., DIJOLS, S., DANSETTE, P. M. AND MANSUY, D.: The substrate binding site of human liver cytochrome P450 2C9 - an approach using designed tienilic acid derivatives and molecular modelling. Biochemistry 34: 10365-10375, 1995.
23. NHAMBURO, P. T., KIMURA, S., MCBRIDE, O. W., KOZAK, C. A., GELBOIN, H. V. AND GONZALEZ, F. J.: The human CYP2F gene subfamily: Identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression and chromosome mapping. Biochemistry 29: 5491-5499, 1990.
24. PEARCE, R., GREENAWAY, D. AND PARKINSON, A: Species differences and inter-individual variation in liver microsomal cytochrome P450 2A (CYP2A) enzymes: Effects on coumarin, dicoumarol and testosterone oxidation. Arch. Biochem. Biophys. 298: 211-225, 1992.
25. PICHARD, L., FABRE, I., FABRE, G., DOMERGUE, J., AUBERT, B. S., MOURAD, G. AND MAUREL, P.: Cyclosporin A drug interactions: Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary culture of human hepatocytes and in liver microsomes. Drug Metab. Disp. 18: 595-606, 1990.
26. RETTENMEIER, A. W., GORDON, W. P., PRICKETT, K. S., LEVY, R. H., LOCKARD, J. S., THUMMEL, K. E. AND BAILLIE, T. A.: Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid. Drug Metab. Dispos. 14: 443-453, 1986.
27. 4 VPA, a toxic metabolite of valproic acid. Science 235: 890-893, 1987.
28. RETTIE, A. E., BOBERG, M., RETTENMEIER, A. W. AND BAILLIE, T. A.: Cytochrome P-450-catalyzed desaturation of valproic acid in vitro. J. Biol. Chem. 263: 13733-13738, 1988.
29. RETTIE, A. E., EDDY, A. C., HEIMARK, L., GIBALDI, M. AND TRAGER, W. F.: Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab. Dispos. 17: 265-270, 1989.
30. RETTIE, A. E., SHEFFELS, P. R., KORZEKWA, K. R., GONZALEZ, F. J., PHILPOT, R. M. AND BAILLIE, T. A.: CYP4 isozyme specificity and the relationship between ω-hydroxylation and terminal desaturation of valproic acid. Biochemistry 34: 7889-7895, 1995.
31. SADEQUE, A. J. M., EDDY, A. C., MEIER, G. P. AND RETTIE, A. E.: Stereoselective sulfoxidation by human flavin-containing monooxygenases: Evidence for catalytic diversity between hepatic, renal and fetal forms. Drug Metab. Dispos. 20: 832-839, 1992.
32. SHIRLEY, M. A., HU, P. AND BAILLIE, T. A.: Stereochemical studies on the beta-oxidation of valproic acid in isolated rat hepatocytes. Drug Metab. Dispos. 21: 580-586, 1993.
33. STEPHENS, J. R. AND LEVY, R. H.: Valproate hepatotoxicity syndrome: hypotheses of pathogenesis. Pharm. Weekbl. Sci. 14: 118-121, 1992.
34. TANG, W., BOREL, A. G., FUJIMIYA, T. AND ABBOTT, F. S.: Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status. Chem. Res. Toxicol. 8: 671-682, 1995.
35. WATKINS, B., WRIGHTON, S. A., MAUREL, P., SCHUETZ, E. G., MENDEZ-PICON, G., PARKER, G. A. AND GUZELIAN, P. S.: Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. U.S.A. 82: 6310-6314, 1985.
36. WRIGHTON, S. A., VANDENBRANDEN, M., STEVENS, J. C., SHIPLEY, L. A., RING, B. J., RETTIE, A. E. AND CASHMAN, J. R.: In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab. Rev. 25: 453-484, 1993.
37. YAMANO, S., TATSUNO, J. AND GONZALEZ, F. J.: The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29: 1322-1329, 1990.